100 related articles for article (PubMed ID: 23409774)
1. Development and implementation of a high-throughput AlphaLISA assay for identifying inhibitors of EZH2 methyltransferase.
Simard JR; Plant M; Emkey R; Yu V
Assay Drug Dev Technol; 2013 Apr; 11(3):152-62. PubMed ID: 23409774
[TBL] [Abstract][Full Text] [Related]
2. Development and validation of reagents and assays for EZH2 peptide and nucleosome high-throughput screens.
Diaz E; Machutta CA; Chen S; Jiang Y; Nixon C; Hofmann G; Key D; Sweitzer S; Patel M; Wu Z; Creasy CL; Kruger RG; LaFrance L; Verma SK; Pappalardi MB; Le B; Van Aller GS; McCabe MT; Tummino PJ; Pope AJ; Thrall SH; Schwartz B; Brandt M
J Biomol Screen; 2012 Dec; 17(10):1279-92. PubMed ID: 22904200
[TBL] [Abstract][Full Text] [Related]
3. Identification of catalytic and non-catalytic activity inhibitors against PRC2-EZH2 complex through multiple high-throughput screening campaigns.
Zhou Y; Du DH; Wang J; Cai XQ; Deng AX; Nosjean O; Boutin JA; Renard P; Yang DH; Luo C; Wang MW
Chem Biol Drug Des; 2020 Oct; 96(4):1024-1051. PubMed ID: 32394628
[TBL] [Abstract][Full Text] [Related]
4. Biological evaluation of tanshindiols as EZH2 histone methyltransferase inhibitors.
Woo J; Kim HY; Byun BJ; Chae CH; Lee JY; Ryu SY; Park WK; Cho H; Choi G
Bioorg Med Chem Lett; 2014 Jun; 24(11):2486-92. PubMed ID: 24767850
[TBL] [Abstract][Full Text] [Related]
5. Quantification of histone H3 Lys27 trimethylation (H3K27me3) by high-throughput microscopy enables cellular large-scale screening for small-molecule EZH2 inhibitors.
Luense S; Denner P; Fernández-Montalván A; Hartung I; Husemann M; Stresemann C; Prechtl S
J Biomol Screen; 2015 Feb; 20(2):190-201. PubMed ID: 25409661
[TBL] [Abstract][Full Text] [Related]
6. Structure-Activity Relationship Studies for Enhancer of Zeste Homologue 2 (EZH2) and Enhancer of Zeste Homologue 1 (EZH1) Inhibitors.
Yang X; Li F; Konze KD; Meslamani J; Ma A; Brown PJ; Zhou MM; Arrowsmith CH; Kaniskan HÜ; Vedadi M; Jin J
J Med Chem; 2016 Aug; 59(16):7617-33. PubMed ID: 27468126
[TBL] [Abstract][Full Text] [Related]
7. Novel 3-methylindoline inhibitors of EZH2: Design, synthesis and SAR.
Ansari A; Satalkar S; Patil V; Shete AS; Kaur S; Gupta A; Singh S; Raja M; Severance DL; Bernales S; Chakravarty S; Hung DT; Pham SM; Herrera FJ; Rai R
Bioorg Med Chem Lett; 2017 Jan; 27(2):217-222. PubMed ID: 27923618
[TBL] [Abstract][Full Text] [Related]
8. Long residence time inhibition of EZH2 in activated polycomb repressive complex 2.
Van Aller GS; Pappalardi MB; Ott HM; Diaz E; Brandt M; Schwartz BJ; Miller WH; Dhanak D; McCabe MT; Verma SK; Creasy CL; Tummino PJ; Kruger RG
ACS Chem Biol; 2014 Mar; 9(3):622-9. PubMed ID: 24304166
[TBL] [Abstract][Full Text] [Related]
9. Targeting histone methyltransferase EZH2 as cancer treatment.
Kondo Y
J Biochem; 2014 Nov; 156(5):249-57. PubMed ID: 25179367
[TBL] [Abstract][Full Text] [Related]
10. Development of a high-throughput fluorescence polarization assay for the discovery of EZH2-EED interaction inhibitors.
Zhu MR; Du DH; Hu JC; Li LC; Liu JQ; Ding H; Kong XQ; Jiang HL; Chen KX; Luo C
Acta Pharmacol Sin; 2018 Feb; 39(2):302-310. PubMed ID: 28858300
[TBL] [Abstract][Full Text] [Related]
11. EZH2 as a potential target in cancer therapy.
McCabe MT; Creasy CL
Epigenomics; 2014 Jun; 6(3):341-51. PubMed ID: 25111487
[TBL] [Abstract][Full Text] [Related]
12. The Importance of Being Me: Magic Methyls, Methyltransferase Inhibitors, and the Discovery of Tazemetostat.
Kuntz KW; Campbell JE; Keilhack H; Pollock RM; Knutson SK; Porter-Scott M; Richon VM; Sneeringer CJ; Wigle TJ; Allain CJ; Majer CR; Moyer MP; Copeland RA; Chesworth R
J Med Chem; 2016 Feb; 59(4):1556-64. PubMed ID: 26769278
[TBL] [Abstract][Full Text] [Related]
13. Weaver Syndrome-Associated EZH2 Protein Variants Show Impaired Histone Methyltransferase Function In Vitro.
Cohen AS; Yap DB; Lewis ME; Chijiwa C; Ramos-Arroyo MA; Tkachenko N; Milano V; Fradin M; McKinnon ML; Townsend KN; Xu J; Van Allen MI; Ross CJ; Dobyns WB; Weaver DD; Gibson WT
Hum Mutat; 2016 Mar; 37(3):301-7. PubMed ID: 26694085
[TBL] [Abstract][Full Text] [Related]
14. SAH derived potent and selective EZH2 inhibitors.
Kung PP; Huang B; Zehnder L; Tatlock J; Bingham P; Krivacic C; Gajiwala K; Diehl W; Yu X; Maegley KA
Bioorg Med Chem Lett; 2015 Apr; 25(7):1532-7. PubMed ID: 25746813
[TBL] [Abstract][Full Text] [Related]
15. An orally bioavailable chemical probe of the Lysine Methyltransferases EZH2 and EZH1.
Konze KD; Ma A; Li F; Barsyte-Lovejoy D; Parton T; Macnevin CJ; Liu F; Gao C; Huang XP; Kuznetsova E; Rougie M; Jiang A; Pattenden SG; Norris JL; James LI; Roth BL; Brown PJ; Frye SV; Arrowsmith CH; Hahn KM; Wang GG; Vedadi M; Jin J
ACS Chem Biol; 2013; 8(6):1324-34. PubMed ID: 23614352
[TBL] [Abstract][Full Text] [Related]
16. Convergent evolution of chromatin modification by structurally distinct enzymes: comparative enzymology of histone H3 Lys²⁷ methylation by human polycomb repressive complex 2 and vSET.
Swalm BM; Hallenbeck KK; Majer CR; Jin L; Scott MP; Moyer MP; Copeland RA; Wigle TJ
Biochem J; 2013 Jul; 453(2):241-7. PubMed ID: 23679895
[TBL] [Abstract][Full Text] [Related]
17. Identification of EZH2 and EZH1 small molecule inhibitors with selective impact on diffuse large B cell lymphoma cell growth.
Garapaty-Rao S; Nasveschuk C; Gagnon A; Chan EY; Sandy P; Busby J; Balasubramanian S; Campbell R; Zhao F; Bergeron L; Audia JE; Albrecht BK; Harmange JC; Cummings R; Trojer P
Chem Biol; 2013 Nov; 20(11):1329-39. PubMed ID: 24183969
[TBL] [Abstract][Full Text] [Related]
18. Targeted disruption of the EZH2-EED complex inhibits EZH2-dependent cancer.
Kim W; Bird GH; Neff T; Guo G; Kerenyi MA; Walensky LD; Orkin SH
Nat Chem Biol; 2013 Oct; 9(10):643-50. PubMed ID: 23974116
[TBL] [Abstract][Full Text] [Related]
19. Roles of the EZH2 histone methyltransferase in cancer epigenetics.
Simon JA; Lange CA
Mutat Res; 2008 Dec; 647(1-2):21-9. PubMed ID: 18723033
[TBL] [Abstract][Full Text] [Related]
20. Akt-mediated phosphorylation of EZH2 suppresses methylation of lysine 27 in histone H3.
Cha TL; Zhou BP; Xia W; Wu Y; Yang CC; Chen CT; Ping B; Otte AP; Hung MC
Science; 2005 Oct; 310(5746):306-10. PubMed ID: 16224021
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
